BioMarin Pharmaceutical (NASDAQ: BMRN) is one of 45 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare BioMarin Pharmaceutical to similar businesses based on the strength of its profitability, analyst recommendations, valuation, risk, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a breakdown of current recommendations for BioMarin Pharmaceutical and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioMarin Pharmaceutical 0 6 16 0 2.73
BioMarin Pharmaceutical Competitors 121 768 1643 59 2.63

BioMarin Pharmaceutical presently has a consensus target price of $113.52, suggesting a potential upside of 38.29%. As a group, “Biopharmaceuticals” companies have a potential upside of 10.48%. Given BioMarin Pharmaceutical’s stronger consensus rating and higher probable upside, equities analysts plainly believe BioMarin Pharmaceutical is more favorable than its competitors.


This table compares BioMarin Pharmaceutical and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioMarin Pharmaceutical -12.45% -4.61% -3.21%
BioMarin Pharmaceutical Competitors -12,981.68% 18.16% -23.88%

Risk and Volatility

BioMarin Pharmaceutical has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical’s competitors have a beta of 1.18, meaning that their average stock price is 18% more volatile than the S&P 500.

Valuation and Earnings

This table compares BioMarin Pharmaceutical and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
BioMarin Pharmaceutical $1.20 billion -$106.70 million -91.21
BioMarin Pharmaceutical Competitors $579.41 million $241.76 million -7.18

BioMarin Pharmaceutical has higher revenue, but lower earnings than its competitors. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

97.6% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 44.9% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 1.9% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


BioMarin Pharmaceutical beats its competitors on 8 of the 12 factors compared.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with's FREE daily email newsletter.